Compare NCSM & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCSM | ATYR |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 79.2M |
| IPO Year | 2017 | 2015 |
| Metric | NCSM | ATYR |
|---|---|---|
| Price | $39.01 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 14.6K | ★ 2.0M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $178,000,000.00 | $190,000.00 |
| Revenue This Year | $11.25 | N/A |
| Revenue Next Year | $7.76 | $18,728.88 |
| P/E Ratio | $8.82 | ★ N/A |
| Revenue Growth | ★ 16.49 | N/A |
| 52 Week Low | $23.89 | $0.64 |
| 52 Week High | $53.69 | $7.29 |
| Indicator | NCSM | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 41.75 |
| Support Level | $39.00 | $0.70 |
| Resistance Level | $40.69 | $0.85 |
| Average True Range (ATR) | 1.51 | 0.05 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 13.36 | 19.29 |
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.